TransCode Therapeutics (RNAZ) Institutional Ownership $7.94 +0.93 (+13.27%) Closing price 04:00 PM EasternExtended Trading$7.80 -0.14 (-1.76%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for TransCode Therapeutics (NASDAQ:RNAZ)Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$543.29MNumber ofInstitutional Sellers(last 12 months)0 Get RNAZ Insider Trade Alerts Want to know when executives and insiders are buying or selling TransCode Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RNAZ Institutional Buying and Selling by Quarter TransCode Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/14/2025 Anson Funds Management LP1,462,112$724K0.1%N/A6.264% 5/9/2025 Warberg Asset Management LLC50,000$25K0.0%N/A0.214% 11/1/2024 Sheets Smith Wealth Management50,138$29K0.0%+149.0%0.290% 5/20/2024 Virtu Financial LLC55,329$37K0.0%N/A0.836% 11/15/2023 Sabby Management LLC250,309$126K0.1%+32.8%12.330% 4/21/2022 K.J. Harrison & Partners Inc19,987$58K0.0%+24.9%0.155% 2/4/2022 Redmond Asset Management LLC88,010$224K0.1%N/A0.682% 1/26/2022 K.J. Harrison & Partners Inc16,000$41K0.0%N/A0.124% 11/16/2021ACT Capital L.L.C.50,000$150K0.1%N/A0.387% 11/16/2021National Asset Management Inc.25,000$75K0.0%N/A0.194% 11/16/2021 Two Sigma Securities LLC33,314$100K0.0%N/A0.258% 11/12/2021 AIGH Capital Management LLC1,270,500$3.80M0.8%N/A9.845% (Data available from 1/1/2016 forward) RNAZ Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RNAZ shares? During the previous two years, the following institutional investors and hedge funds held shares of TransCode Therapeutics shares: Anson Funds Management LP ($724K), Sabby Management LLC ($126K), Virtu Financial LLC ($37K), and Sheets Smith Wealth Management ($29K), Warberg Asset Management LLC ($25K).Learn more on RNAZ's institutional investors. Which institutional investors have been buying TransCode Therapeutics stock? The following institutional investors have purchased TransCode Therapeutics stock in the last 24 months: Anson Funds Management LP ($1.46M), Sabby Management LLC ($61.87K), Virtu Financial LLC ($55.33K), Warberg Asset Management LLC ($50K), and Sheets Smith Wealth Management ($30K). How much institutional buying is happening at TransCode Therapeutics? Institutional investors have bought a total of 1,659,313 shares in the last 24 months. This purchase volume represents approximately $39.63B in transactions. Related Companies FibroBiologics Institutional Ownership Dyadic International Institutional Ownership bluebird bio Institutional Ownership Kezar Life Sciences Institutional Ownership FibroGen Institutional Ownership Marinus Pharmaceuticals Institutional Ownership MiNK Therapeutics Institutional Ownership Allakos Institutional Ownership Scilex Institutional Ownership CalciMedica Institutional Ownership This page (NASDAQ:RNAZ) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
